Izencitinib (TD-1473) is an orally active, nonselective, gut-defined JAK inhibitor. Izencitinib (TD-1473) can be used in ulcerative colitis studies.
|Solubility (25°C)||DMSO ≥ 20 mg/mL|
Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Related JAK Products|
SDC-1802 is a JAK1/TYK2 inhibitor that can be used in studies related to systemic lupus erythematosus.
OST-246 is an inhibitor of JAK3, MAP3K11, and TYK2 for studies related to autoimmune diseases and inflammation.
NDI-031232 is a TYK2 inhibitor.
NDI-031301 is a TYK2 inhibitor.
NDI-031407 is a TYK2 inhibitor for studies related to endocrine metabolic diseases and psoriasis.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.